Evaluation Of Clinical Pharmacy Services in Patients Receiving Antithrombotic Treatment

NCT06193473 | Completed

• 1 other identifier: Pharm. Role in Cardiology
• Study Type: interventional
• Target: 400
• Locations: 1 country
• Sites: 1

Brief Summary

Clinical pharmacy services aim to enhance patient outcomes and reduce the risk of potential drug-related harm by offering patient-centred pharmaceutical care. In the hospital setting, clinical pharmacists collaborate with physicians as part of a multidisciplinary team to identify and prevent DRPs (Drug-related problems). Clinical pharmacist interventions encompass 'any action initiated by a pharmacist that directly results in patient management or a modification in medication.' The favourable clinical and economic impacts of interventions have been well-established for decades. Clinical pharmacists have played an important role in ensuring the effective and correct use of medicines in many settings. This study aims to investigate the clinical pharmacy services provided by clinical pharmacists to patients receiving antithrombotic therapy. For this study, patients were divided into two groups: a control group and an intervention group. A comprehensive medication review will be conducted by the clinical pharmacist for both the control and intervention groups. Drug-related problems such as drug selection, dose errors, possible drug-drug interactions, and inappropriate drug use, will be identified. In the control group, no interventions will be made by the clinical pharmacist. In the intervention group, solution recommendations for identified and clinically significant issues will be presented to the physician, and the provided services will be documented. Furthermore, the groups will be evaluated for whether there are any hospital readmissions within 1 and 3 months following discharge for the patients.

Conditions

Cardiovascular Diseases; Drug Use

Keywords

clinical pharmacist; antithrombotic drugs; drug-related problems; cardiovascular diseases

Outcome Measures

Primary Outcomes (3)

• Acceptance rate of suggested intervention (number)

  Acceptance rate of suggested intervention. Medication-related problems and recommendations are classified according to PCNE (Pharmaceutical Care Network Europe) version 9.1. It was recorded how many suggestions were made in the intervention group and how many of these suggestions were accepted.

  From the date of randomization until there are 200 patient participants in each group. Average 1 year.

• Length of hospital stay (days)

  Length of hospital stay

  From date of randomization until the date of discharge from the hospital, assessed up to 1 year.

• Within three months readmission (number of patients re-admitted to hospital)

  In order to determine which group of patients has the highest number of hospital re-admissions and to evaluate whether there is a significant difference between the groups.

  Whether patients were readmitted to the hospital within three months of discharge or transfer.

Study Arms (2)

Control Group: Group in which only observation is made by the clinical pharmacist

NO INTERVENTION

For patients in this group, no intervention (i.e. recommendation) will be made to physicians by the clinical pharmacist. Within the intervention group, patient characteristics such as the length of hospital stay, reason for hospitalization, underlying conditions, and the appropriateness of prescribed medications were evaluated for the patients who received antithrombotic treatment and met the inclusion criteria. The participant will take standard treatment. Evaluations will be recorded. Follow-up was performed to determine whether the patients had a re-admission within 3 months.

Intervention Group: Group to which the clinical pharmacist makes recommendations

EXPERIMENTAL

For patients in this group, intervention (i.e. recommendation) will be made to physicians by the clinical pharmacist. Within the intervention group, patient characteristics such as the length of hospital stay, reason for hospitalization, underlying conditions, and the appropriateness of prescribed medications were evaluated for the patients who received antithrombotic treatment and met the inclusion criteria. Through medication reviews, evaluations were made to identify drug-related problems and provide solutions to these problems. The clinical pharmacist provided recommendations to the physicians regarding significant clinically important problems. Additionally, follow-up was performed to determine whether the patients had a re-admission within 3 months.

Behavioral: Intervention Group: Group to which the clinical pharmacist makes recommendations

Interventions

Intervention Group: Group to which the clinical pharmacist makes recommendations BEHAVIORAL

The drugs administered to patients within 24-48 hours after hospitalization were recorded. A detailed medication review will be conducted by the clinical pharmacist during the participants' hospitalization.As a result of a comprehensive evaluation, recommendations were made to doctors regarding drug-related problems and were recorded.

Intervention Group: Group to which the clinical pharmacist makes recommendations

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Being 18 years and older.
• Receiving antithrombotic treatment.
• Having complete biochemical and complete blood count values collected at least twice, with two-day medication information fully entered into the hospital system.
• Patients who could be evaluated by the clinical pharmacist for at least 24 hours within the intervention group.

You may not qualify if:

• Being under 18 years old.
• Not using antithrombotic medication.
• Patients whose biochemical and complete blood count values were not collected twice and whose two-day medication information was not fully recorded in the hospital system.
• Patients in the intervention group whom the clinical pharmacist did not see for at least 24 hours (weekend hospital admission followed by Monday morning discharge, Friday admission with weekend discharge, etc.) were excluded from the study.

Sponsors & Collaborators

• Bezmialem Vakif University: lead

Study Sites (1)

Bezmialem Vakıf Üniversitesi

Istanbul, Fatih, 34096, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Cardiovascular Diseases

Study Officials

• Fikret Vehbi Izzettin, Prof.Dr.

  Bezmialem Vakıf Üniversitesi

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: PARTICIPANT
• Purpose: HEALTH SERVICES RESEARCH
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: December 5, 2023
• First Posted: January 5, 2024
• Study Start: November 30, 2021
• Primary Completion: June 30, 2022
• Study Completion: November 30, 2022
• Last Updated: January 5, 2024

Record last verified: 2024-01

Locations

TU (1)